Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug603 | Blood group determination Wiki | 1.00 |
| drug3090 | Probiotic Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D016638 | Critical Illness NIH | 0.12 |
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
When the COVID-19 virus infects a person, it enters the lung epithelial cells of its host and uses its genetic material to replicate. The pulmonary epithelial cells of a part of the population, known as "secretors", are capable of expressing the antigens of the "ABO" system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system. When the virus replicates in an "secreting" individual, the antigens of the "ABO" system of the infected individual will be present on the surface of the viruses formed in his/her lungs. It was shown in 2003 that the response of a given individual to the transmission of a virus depends on his/her blood group and on the antigens of the "ABO" system carried by the virus. A patient of group "O" would thus defend himself much better against a virus carrying antigens of blood group "A", the natural antibodies "anti-A" of the patient reducing the ability of the virus to bind to its specific receptor on pulmonary epithelial cells, to penetrate them to replicate itself. The first data collected in Wuhan (China) seems to confirm this hypothesis. A COVID-19 virus transmission model can therefore be established on the basis of blood groups. In order to reduce the spread of the virus among nursing staff, it is possible to establish a preferential algorithm for patient management based on the "ABO" and "Lewis" blood groups of patients and "ABO" of nursing staff in health care units, if operational and human conditions allow.
Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: baselineDescription: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: Day 4Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: Week 1Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: Week 2Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: Week 3Description: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: baselineDescription: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: Day 4Description: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: Week 1Description: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: Week 2Description: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: Week 3Description: Blood group (ABO/LE)
Measure: Blood group Time: baselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports